← FDA DRUG APPROVALS

FDA ANDA · ANDA206204

PIPERACILLIN AND TAZOBACTAM

Sponsor: FRESENIUS KABI USA

APPLICATION
ANDA206204
TYPE
ANDA
ORIGINAL APPROVAL
2018-05-11
LATEST ACTION
2018-05-11
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

PIPERACILLIN AND TAZOBACTAMDiscontinued
PIPERACILLIN SODIUM EQ 12GM BASE/VIAL, TAZOBACTAM SODIUM EQ 1.5GM BASE/VIAL · INJECTABLE · INJECTION

Approval history

2018-05-11UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →